ArticleInternational immunology2023
Suppressive mechanisms of regulatory B cells in mice and humans.
Article in International immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Selective decreases in regulatory B-cell (Breg) subsets in active uveitis: IL-10+CD19+CD24hiCD38hiBregs in patients and B10 Bregs in mice.International immunology · 2026Article
- Endothelial cell glycogen synthase kinase 3β promotes lipotoxic endotheliopathy and liver inflammation in MASH.JCI insight · 2026Article
- Review
- The Dual Role of Interleukin-10 in Sepsis: Research Progress and Therapeutic Prospects.Inflammation · 2026Review
- The Complexity of Immunoglobulin A Immune Responses in Respiratory Syncytial Virus Infection.Viruses · 2026Review
- Distinct B Cell Subsets Changes as Potential Biomarkers of Response to Biologic Therapy in Crohn's Disease.International journal of molecular sciences · 2025Article
- Exploring the role of APRIL in autoimmunity: implications for therapeutic targeting in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome.Frontiers in immunology · 2025Review
- The immune tolerance role of Bregs in inhibiting human inflammatory diseases, with a focus on diabetes mellitus.Frontiers in immunology · 2025Review
- Recent advances in regulatory immune cells: exploring the world beyond Tregs.Frontiers in immunology · 2025Review
- Overview of the Different Classes of Small RNAs During B-Cell Development.Methods in molecular biology (Clifton, N.J.) · 2025Review
- The half-century odyssey of regulatory B cells: from Breg discovery to emerging frontiers.Frontiers in immunology · 2025Review
- Follicle-like niches outside the cortex? 3D phase-contrast µCT revealed medullary B cell nodules in mucosa-draining lymph nodes.Frontiers in immunology · 2025Article
- The Role of Regulatory B Lymphocytes in Allergic Diseases.Biomedicines · 2024Review
- B cells and atherosclerosis: A HIV perspective.Journal of cellular physiology · 2024Review
- Momordicine-I Suppresses Head and Neck Cancer Growth by Reprogrammimg Immunosuppressive Effect of the Tumor-Infiltrating Macrophages and B Lymphocytes.Molecular cancer therapeutics · 2024Article
- Mechanisms underlying immunosuppression by regulatory cells.Frontiers in immunology · 2024Review
- CD5: from antiquated T cell marker to immunotherapy's new hope.Signal transduction and targeted therapy · 2023Article
- The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B cells include immune-suppressive fractions, called regulatory B cells (Bregs), which regulate inflammation primarily through an interleukin 10 (IL-10)-mediated inhibitory mechanism. Several B-cell fractions have been reported as IL-10-producing Bregs in murine disease models and human inflammatory responses including autoimmune diseases, infectious diseases, cancer and organ-transplant rejection. Although the suppressive functions of Bregs have been explored through the hallmark molecule IL-10, inhibitory cytokines and membrane-binding molecules other than IL-10 have also been demonstrated to contribute to Breg activities. Transcription factors and surface antigens that are characteristically expressed in Bregs are also being elucidated. Nevertheless, defining Bregs is still challenging because their active periods and differentiation stages vary among disease models. The identity of the diverse Breg fractions is also under debate. In the first place, since regulatory functions of Bregs are mostly evaluated by ex vivo stimulation, the actual in vivo phenotypes and functions may not be reflected by the ex vivo observations. In this article, we provide a historical overview of studies that established the characteristics of Bregs and review the various suppressive mechanisms that have been reported to be used by Bregs in murine and human disease conditions. We are only part-way through but the common phenotypes and functions of Bregs are still emerging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.